Compare POWL & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | POWL | TGTX |
|---|---|---|
| Founded | 1947 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 7.6B |
| IPO Year | 1995 | 2008 |
| Metric | POWL | TGTX |
|---|---|---|
| Price | $208.74 | $50.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $184.25 | $49.80 |
| AVG Volume (30 Days) | 819.2K | ★ 2.3M |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.14% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | ★ 3.81 | 0.17 |
| Revenue | ★ $448,716,000.00 | $2,785,000.00 |
| Revenue This Year | $11.20 | $49.08 |
| Revenue Next Year | $9.12 | $26.69 |
| P/E Ratio | ★ $54.48 | $290.41 |
| Revenue Growth | ★ 13.34 | N/A |
| 52 Week Low | $178.05 | $26.76 |
| 52 Week High | $612.50 | $59.30 |
| Indicator | POWL | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.21 | 44.60 |
| Support Level | $181.33 | $28.57 |
| Resistance Level | $248.33 | $58.08 |
| Average True Range (ATR) | 14.39 | 2.39 |
| MACD | 1.39 | -0.64 |
| Stochastic Oscillator | 38.17 | 37.80 |
Powell Industries Inc is a United States-based company that develops, designs, manufactures, and services custom-engineered equipment and systems for electrical energy distribution, control, and monitoring. The company's principal products comprise integrated power control room substations, custom-engineered modules, electrical houses, traditional and arc-resistant distribution switchgear and control gear, and so on. These products are applied in oil and gas refining, offshore oil and gas production, petrochemical, pipeline, terminal, mining and metals, light-rail traction power, electric utility, pulp and paper, and other heavy industrial markets. The company generates the majority of its sales from the United States, and the rest from Canada, Europe, Asia Pacific, and other regions.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.